{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial on Pulmonary Endarterectomy for Chronic Thromboembolic Pulmonary Hypertension"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "This randomised controlled trial was conducted across four leading CTEPH centers."
      },
      "Participants": {
        "score": 2,
        "evidence": "Eligible participants were adults with a confirmed diagnosis of operable CTEPH."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants were randomised to either undergo PEA or receive standard medical therapy."
      },
      "Objective": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the change in pulmonary vascular resistance (PVR) at 6 months post-intervention."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was performed using a computer-generated sequence, with allocation concealment ensured through sealed envelopes."
      },
      "Blinding": {
        "score": 1,
        "evidence": "Blinding was applied to outcome assessors."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "A total of 200 participants were randomised: 100 to the PEA group and 100 to the control group, during the recruitment period from January 2020 to June 2021."
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "In the intention-to-treat analysis, 98 participants in the PEA group and 97 in the control group were analysed."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The PEA group demonstrated a significant reduction in PVR compared to the control group (mean difference = 5.2 mm Hg, 95% CI 3.1 to 7.3; p = 0.01)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were observed in 3/100 (3%) of the PEA group and 1/98 (1%) of the control group, primarily mild gastrointestinal side-effects."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 1,
        "evidence": "This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors."
      }
    },
    "total_score": 21,
    "max_score": 25
  },
  "model": "gpt-4o"
}